AKBA:NSD-Akebia Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.14

Change

+0.09 (+2.95)%

Market Cap

USD 0.44B

Volume

6.01M

Average Target Price

USD 6.80 (+116.56%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+6.36 (+2.82%)

USD58.65B 22.10 18.26
REGN Regeneron Pharmaceuticals, Inc

+15.96 (+3.08%)

USD55.27B 18.98 14.64
MRNA Moderna, Inc

-4.64 (-3.58%)

USD51.30B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+2.01 (+1.28%)

USD34.27B 36.37 33.83
SGEN Seagen Inc

+3.03 (+1.63%)

USD33.25B 70.15 70.76
RPRX Royalty Pharma plc

-0.10 (-0.19%)

USD32.48B 22.60 11.90
BGNE BeiGene, Ltd

+11.68 (+3.39%)

USD31.01B N/A N/A
GMAB Genmab A/S

-0.07 (-0.16%)

USD28.77B 26.59 3.08
BNTX BioNTech SE

+3.11 (+3.06%)

USD24.46B -99,999.99 N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AKBA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.14% 48% F 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.14% 48% F 68% D+
Trailing 12 Months  
Capital Gain -60.40% 5% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.40% 5% F 2% F
Trailing 5 Years  
Capital Gain -58.19% 30% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.19% 29% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain 10.63% 53% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.63% 53% F 63% D
Risk Return Profile  
Volatility (Standard Deviation) 68.75% 38% F 17% F
Risk Adjusted Return 15.46% 47% F 43% F
Market Capitalization 0.44B 55% F 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.40 93% A 71% C-
Price / Cash Flow Ratio -1.71 16% F 62% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -99.54% 29% F 11% F
Return on Invested Capital -49.80% 60% D- 19% F
Return on Assets -16.34% 76% C 22% F
Debt to Equity Ratio 19.62% 50% F 65% D
Technical Ratios  
Short Ratio 5.22 33% F 25% F
Short Percent 22.81% 6% F 8% F
Beta 2.10 22% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector